Edaravone dexborneol in acute ischaemic stroke: an updated GRADE assessed systematic review and meta-analysis with trial sequential analysis
Despite three decades of neuroprotective failures in acute ischaemic stroke (AIS), edaravone dexborneol (EDB) achieved regulatory approval in China by demonstrating superiority over edaravone monotherapy. The only prior meta-analysis evaluated a single functional endpoint, excluded four subsequent studies including the...